UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 30, 2014

STERIS Corporation

(Exact Name of Registrant as Specified in Charter)

Ohio (State or Other Jurisdiction of Incorporation) 1-14643 (Commission File Number) 34-1482024 (IRS Employer Identification No.)

5960 Heisley Road, Mentor, Ohio (Address of Principal Executive Offices)

44060-1834 (Zip Code)

Registrant's telephone number, including area code: (440) 354-2600

 $\begin{tabular}{ll} Not \ Applicable \\ (Former name or former address, if changed since last report.) \end{tabular}$

ck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following risions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02. Results of Operations and Financial Condition.

On August 5, 2014, STERIS Corporation ("STERIS" or "Company") issued a press release announcing financial results for its fiscal 2015 first quarter ended June 30, 2014. A copy of this press release is attached hereto as Exhibit 99.1.

The information contained in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this Item 2.02 of this Current Report on Form 8-K shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933.

ITEM 5.07. Submission of Matters to a Vote of Security Holders.

At the STERIS 2014 Annual Meeting of Shareholders ("Meeting"), held on July 30, 2014, shareholders voted on the matters specified below, with the final voting results as specified. According to the certified list of shareholders, there were 59,243,482 Common Shares of the Company outstanding and entitled to vote at the Meeting. There were present at the Meeting, in person or by proxy, the holders of 54,226,854 Common Shares or 91.53% of the outstanding Common Shares of the Company, constituting a quorum.

1. The nominees named below were elected to the Board of Directors, each for a one-year term, and the results of the vote were as follows:

Nominee	Votes For	Votes Withheld	Broker Non-Votes
Richard C. Breeden	51,065,119	99,191	3,062,544
Cynthia L. Feldmann	51,084,461	79,849	3,062,544
Jacqueline B. Kosecoff	50,846,219	318,091	3,062,544
David B. Lewis	51,084,343	79,967	3,062,544
Kevin M. McMullen	50,814,668	349,642	3,062,544
Walter M Rosebrough, Jr.	51,063,011	101,299	3,062,544
Mohsen M. Sohi	51,081,945	82,365	3,062,544
John P. Wareham	50,874,044	290,266	3,062,544
Loyal W. Wilson	50,811,023	353,287	3,062,544
Michael B. Wood	51,075,172	89,138	3,062,544

2. The non-binding advisory proposal to approve the compensation of our named executive officers was approved, and the results of the vote were as follows:

Votes for	49,825,554
Votes against	967,842
Abstentions	370,914
Broker non-votes	3,062,544

3. The proposal to ratify the appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the fiscal year ended March 31, 2015 was approved, and the results of the vote were as follows:

Votes for	53,973,477
Votes against	189,887
Abstentions	63 490

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press Release issued by STERIS Corporation on August 5, 2014 announcing financial results for its fiscal 2015 first quarter ended June 30, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STERIS CORPORATION

By /s/ J. Adam Zangerle

J. Adam Zangerle Vice President, General Counsel, and Secretary

Date: August 5, 2014

EXHIBIT INDEX

Exhibit No. Description

Press Release issued by STERIS Corporation on August 5, 2014 announcing financial results for its fiscal 2015 first quarter ended June 30, 2014.



STERIS CORPORATION NEWS ANNOUNCEMENT FOR IMMEDIATE RELEASE

STERIS CORPORATION ANNOUNCES FISCAL 2015 FIRST QUARTER RESULTS

- Double digit growth in-line with expectations
- The Company affirms its outlook for fiscal 2015
- Board of Directors increases quarterly dividend by two cents to \$0.23 per share

Mentor, Ohio (August 5, 2014)—STERIS Corporation (NYSE: STE) today announced financial results for its fiscal 2015 first quarter ended June 30, 2014. Fiscal 2015 first quarter revenue increased 12% to \$412.6 million compared with \$367.7 million in the first quarter of fiscal 2014, driven by growth in the Company's Healthcare and Isomedix segments. Organic revenue growth in the first quarter of fiscal 2015 was 3%.

As reported, fiscal 2015 first quarter net income was \$24.5 million, or \$0.41 per diluted share, compared with net income of \$32.3 million, or \$0.54 per diluted share in the first quarter of fiscal 2014, which includes a \$0.15 tax benefit associated with the Company's prior European restructuring effort. Adjusted earnings in the first quarter of fiscal 2015 increased to \$0.54 per diluted share compared with \$0.44 per diluted share in the first quarter of fiscal 2014. Please refer to the attached schedules for additional information, including reconciliations of adjusted "non-GAAP financial measures" to reported results.

"We are pleased to have a strong start to our fiscal year," said Walt Rosebrough, President and Chief Executive Officer of STERIS. "Revenue growth was in-line with our expectations as our consumables business exceeded forecast and offset a little softness in our capital equipment shipments. We believe both of these trends are a matter of timing. As a result, we anticipate that we will achieve our full year outlook of double digit revenue and adjusted earnings growth."

Segment Results

Healthcare revenue in the quarter was \$302.8 million, an increase of 17% compared with \$258.9 million in the first quarter of fiscal 2014. This growth was across the business, with service revenue growth of 43%, consumable revenue increases of 12% and capital equipment revenue was up 1%. Healthcare revenue grew 4% organically excluding the IMS and Eschmann acquisitions. As reported,

STERIS Corporation News Announcement Page 2

operating income for the first quarter of fiscal 2015 was \$18.0 million compared with operating income of \$14.9 million in last year's first quarter. Adjusted operating income was \$29.7 million compared with \$19.7 million in the prior year first quarter, driven by organic volume growth, product mix and acquisitions.

Life Sciences first quarter revenue declined 2% to \$58.6 million compared with \$59.9 million in the first quarter of fiscal 2014. While consumable revenue increased 6% and service revenue grew 9%, it was not enough to offset an 18% decline in capital equipment revenue, which tends to vary by quarter. Life Sciences first quarter fiscal 2015 operating income was \$11.9 million compared with \$12.5 million in last year's first quarter, primarily reflecting the decline in volume.

Fiscal 2015 first quarter revenue for Isomedix Services was \$51.2 million compared with \$48.2 million in the same period last year, an increase of 6%. Operating income for the first quarter of fiscal 2015 increased to \$16.2 million compared with \$14.7 million in the first quarter of last year, as Isomedix continues to fill the recently expanded capacity.

Cash Flow

Net cash provided by operations for the first quarter of fiscal 2015 was \$46.4 million, compared with \$32.7 million last year. Free cash flow (see note 1) for the first quarter of fiscal 2015 was \$23.1 million, compared with \$11.0 million in the prior year. The improvement in free cash flow is primarily due to working capital improvements.

Outlook

Based upon current trends, the Company is affirming its original outlook for fiscal 2015, which includes revenue growth in the range of 15-17% and adjusted earnings per diluted share in the range of \$2.78 to \$2.91 for the full fiscal year. Please see the Company's earnings release dated May 8, 2014 for a more detailed outlook.

Dividend Announcement

The Company also announced today that STERIS's Board of Directors has authorized a two cent increase in its quarterly dividend to \$0.23 per common share, representing the ninth consecutive year of dividend increases. The dividend is payable September 23, 2014 to shareholders of record at the close of business on August 26, 2014.

STERIS Corporation News Announcement Page 3

Conference Call

In conjunction with this release, STERIS Corporation management will host a conference call today at 10:00 a.m. Eastern time. The conference call can be heard live over the Internet at www.steris-ir.com or via phone by dialing 1-800-369-8428 in the United States and Canada, and 1-773-799-3378 internationally, then referencing the password "STERIS".

For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. Eastern time either over the Internet at www.steris-ir.com or via phone by calling 1-800-685-6364 in the United States and Canada, and 1-402-998-0553 internationally.

About STERIS

The mission of STERIS Corporation is to help our Customers create a healthier and safer world by providing innovative healthcare and life science product and service solutions around the globe. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit www.steris.com

(1) Free cash flow is a non-GAAP number used by the Company as a measure to gauge its ability to fund future debt principal repayments, growth outside of core operations, repurchase common shares, and pay cash dividends. Free cash flow is defined as cash flows from operating activities less purchases of property, plant, equipment and intangibles, net, plus proceeds from the sale of property, plant, equipment and intangibles. STERIS's calculation of free cash flow may vary from other companies.

The press release and referenced conference call may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry, products or activities that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this press release and the referenced conference call, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," "outlook," "impact," "potential," "confidence," "improve," "optimistic," "deliver," "comfortable," "trend", and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, actions of regulatory agencies, and changes in laws, government regulations, labeling or product approvals or the application or

STERIS Corporation News Announcement Page 4

interpretation thereof. Other risk factors are described herein and in the Company's Form 10-K and other securities filings. Many of these important factors are outside STERIS's control. No assurances can be provided as to any result or the timing of any outcome regarding matters described in the press release, or the referenced conference call or otherwise with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, consent decree, cost reductions, business strategies, earnings or revenue trends or future financial results. References to products and the consent decree are summaries only and should not be considered the specific terms of the decree or product clearance or literature. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing or costs that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products or applications or business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings, certifications, regulations, regulatory actions, including without limitation those relating to FDA warning notices or letters, government investigations, the outcome of any pending FDA requests, inspections or submissions, or other requirements or standards may delay, limit or prevent new product introductions, affect the production and marketing of existing products or services or otherwise affect Company performance, results, prospects or value, (d) the potential of international unrest, economic downturn or effects of currencies, tax assessments, adjustments, or anticipated rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services, (f) the possibility that anticipated growth, cost savings, new product acceptance, performance or approvals, or other results may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with our business, industry or initiatives including, without limitation, the consent decree, or those matters described in our Form 10-K for the year ended March 31, 2014 and other securities filings, may adversely impact Company performance, results, prospects or value, (g) the possibility that anticipated financial results or benefits of recent acquisitions or of our restructuring efforts will not be realized or will be other than anticipated, (h) the effects of contractions in credit availability, as well as the ability of our Customers and suppliers to adequately access the credit markets when needed, and (i) those risks described in our securities filings including our Annual Report on Form 10-K for the year ended March 31, 2014, and other securities filings.

Contact: Julie Winter, Director, Investor Relations at 440-392-7245.

STERIS Corporation Consolidated Condensed Statements of Operations (In thousands, except per share data)

	Three Moi Jun	nths Ended e 30,
	2014	2013
D	(Unaudited)	(Unaudited)
Revenues	\$412,643	\$367,652
Cost of revenues	242,664	220,806
Cost of revenues—Restructuring	(114)	
Cost of revenues, net	242,550	220,806
Gross profit	170,093	146,846
Operating expenses:		
Selling, general, and administrative	113,688	93,929
Research and development	12,409	11,853
Restructuring expense	(172)	52
Total operating expenses	125,925	105,834
Income from operations	44,168	41,012
Non-operating expense, net	4,462	4,739
Income tax expense	15,169	3,956
Net income	\$ 24,537	\$ 32,317
Earnings per common share (EPS) data:		
Basic	\$ 0.41	\$ 0.55
Diluted	\$ 0.41	\$ 0.54
Cash dividends declared per common share outstanding	\$ 0.21	\$ 0.19
Weighted average number of common shares outstanding used in EPS computation:		
Basic number of common shares outstanding	59,169	59,005
Diluted number of common shares outstanding	59,814	59,790
STEDIS Corporation		

STERIS Corporation Consolidated Condensed Balance Sheets

(In thousands)

	June 30, 2014 (Unaudited)	March 31, 2014
Assets		
Current assets:		
Cash and cash equivalents	\$ 157,936	\$ 152,802
Accounts receivable, net	284,194	313,686
Inventories, net	179,593	155,146
Other current assets	55,174	53,111
Total Current Assets	676,897	674,745
Property, plant, and equipment, net	475,222	454,410
Goodwill and intangible assets, net	890,089	747,715
Other assets	10,258	10,292
Total Assets	\$2,052,466	\$1,887,162
Liabilities and Equity		
Current liabilities:		
Accounts payable	\$ 88,046	\$ 102,430
Other current liabilities	143,304	152,076
Total Current Liabilities	231,350	254,506
Long-term debt	658,740	493,480
Other liabilities	96,372	97,930
Equity	1,066,004	1,041,246
Total Liabilities and Equity	\$2,052,466	\$1,887,162

STERIS Corporation Segment Data (In thousands)

		Three Months Ended June 30,	
	2014 (Unaudited)	2013 (Unaudited)	
	(Onaudited)	(Ollauditeu)	
	\$302,810	\$258,888	
	58,614	59,915	
	51,193	48,224	
nts	412,617	367,027	
orate and Other	26	625	
evenues	<u>\$412,643</u>	\$367,652	
egment Revenues	Three Moi Jun 2014	nths Ended e 30, 2013	
	Three Moi	nths Ended e 30,	
erating Income:	Three Moi Jun 2014	nths Ended e 30, 2013	
perating Income:	Three Mon Jun 2014 (Unaudited)	this Ended e 30, 2013 (Unaudited) \$ 14,947 12,539	
Operating Income: chcare Sciences RIS Isomedix Services	Three Mon June 2014 (Unaudited) \$ 17,966	nths Ended e 30, 2013 (Unaudited) \$ 14,947	
perating Income: care ciences IS Isomedix Services Reportable Segments	Three Moi Jun 2014 (Unaudited) \$ 17,966	this Ended e 30, 2013 (Unaudited) \$ 14,947 12,539	
ncome: x Services	Three Mor June 2014 (Unaudited) \$ 17,966 11,945 16,191	ths Ended e 30, 2013 (Unaudited) \$ 14,947 12,539 14,718	

		Three Months Ended June 30,	
	2014 (Unaudited)	2013 (Unaudited)	
Operating Activities:	(Ondunted)	(Ollaudited)	
Net income	\$ 24,537	\$ 32,317	
Non-cash items	21,940	23,321	
Changes in operating assets and liabilities	(124)	(22,941)	
Net cash provided by operating activities	46,353	32,697	
Investing Activities:			
Purchases of property, plant, equipment, and intangibles, net	(23,331)	(21,741)	
Proceeds from sale of property, plant, equipment and intangibles	71	8	
Investments in businesses, net of cash acquired	(179,012)	(115)	
Net cash used in investing activities	(202,272)	(21,848)	
Financing Activities:			
Proceeds under credit facilities, net	165,260	21,410	
Deferred financing fees and debt issuance costs	_	(43)	
Repurchases of common shares	(5,319)	(4,775)	
Cash dividends paid to common shareholders	(12,459)	(11,244)	
Stock option and other equity transactions, net	7,150	8,482	
Tax benefit from share-based compensation	3,835	718	
Net cash used in and provided by financing activities	158,467	14,548	
Effect of exchange rate changes on cash and cash equivalents	2,586	(1,567)	
Decrease in cash and cash equivalents	5,134	23,830	
Cash and cash equivalents at beginning of period	152,802	142,008	
Cash and cash equivalents at end of period	<u>\$ 157,936</u>	\$ 165,838	

The following table presents a financial measure which is considered to be "non-GAAP financial measures" under Securities Exchange Commission rules. Free cash flow is defined by the Company as cash flows from operating activities less purchases of property, plant, equipment and intangibles, net (capital expenditures) plus proceeds from the sale of property, plant, equipment and intangibles. The Company uses free cash flow as a measure to gauge its ability to fund future principal debt repayments and growth outside of core operations, repurchase common shares, and pay cash dividends. STERIS's calculation of free cash flow may vary from other companies.

	Three Months Ended June 30,	
	2014	2013
	(Unaudited)	(Unaudited)
Calculation of Free Cash Flow:		
Cash flows from operating activities	\$ 46,353	\$ 32,697
Purchases of property, plant, equipment, and intangibles, net	(23,331)	(21,741)
Proceeds from the sale of property, plant, equipment, and intangibles	71	8
Free Cash Flow	\$ 23,093	

	Twelve Months Ended March 31, 2015 (Outlook)*	
Calculation of free cash flow for outlook:	,	
Cash flows from operating activities	\$	230,000
Purchases of property, plant, equipment, and intangibles, net		(95,000)
Free Cash Flow		135,000

^{*} All amounts are estimates.

STERIS Corporation

Non-GAAP Earnings Per Share and Outlook

Non-GAAP financial measures are presented with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision making. These amounts are disclosed so that the reader has the same financial data that management uses with the belief that it will assist investors and other readers in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented.

We believe that the presentation of these non-GAAP financial measures, when considered along with our GAAP financial measures and the reconciliation to the corresponding GAAP financial measures, provide the reader with a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. It is important for the reader to note that the non-GAAP financial measure used may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.

	Three mon June	
	2014 (Unaudited)	2013 (Unaudited)
Net Income per diluted share	\$ 0.41	\$ 0.54
Loss (gain) from fair value adjustment of acquistion related contingent		
consideration	0.02	_
Tax benefit, European restructuring	_	(0.15)
Inventory and property "step up" to fair value, net of tax	0.02	_
Amortization and impairment of purchased intangible assets, net of tax	0.05	0.04
Acquisition related transaction and integration expenses, net of tax	0.04	0.01
Adjusted net income per diluted share	\$ 0.54	\$ 0.44

	Tw	elve months ended March 31, 2015 (Outlook)*
Net Income per diluted share	\$	2.40 — \$2.53
Inventory "step up" to fair value, net of tax		0.02
Amortization and impairment of purchased intangible assets, net of tax		0.02
Acquisition related transaction and integration expenses, net of tax		0.12
Adjusted net income per diluted share	\$	2.78 — \$2.91

^{*} All amounts are estimates.

STERIS Corporation Non-GAAP Financial Measures (In thousands, except per share data)

Non-GAAP financial measures are presented with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision making. These amounts are disclosed so that the reader has the same financial data that management uses with the belief that it will assist investors and other readers in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented.

We believe that the presentation of these non-GAAP financial measures, when considered along with our GAAP financial measures and the reconciliation to the corresponding GAAP financial measures, provide the reader with a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. It is important for the reader to note that the non-GAAP financial measure used may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.

	Three mor June 2014	2013
Gross Profit	(Unaudited) \$ 170,093	(Unaudited) \$ 146,846
Amortization of inventory "step up" to fair value	1,234	_
Restructuring	(114)	_
Adjusted gross profit	\$171,213	\$146,846
Selling, general and administrative expenses	\$ 113,688	\$ 93,929
Amortization and impairment of purchased intangible assets	(5,200)	(4,290)
Amortization of property "step up" to fair value	(23)	_
Acquisition related transaction and integration costs	(3,634)	(708)
(Loss) gain from fair value adjustment of acquistion related contingent consideration	(1,998)	
Adjusted selling, general and administrative expenses	\$102,833	\$ 88,931
Operating income	\$ 44,168	\$ 41,012
Amortization of inventory and property "step up" to fair value	1,257	_
Amortization and impairment of purchased intangible assets	5,200	4,290
Acquisition related transaction and integration costs	3,634	708
Loss (gain) from fair value adjustment of acquistion related contingent consideration	1,998	_
Restructuring	(286)	52
Adjusted operating income	\$ 55,971	\$ 46,062
Net income	\$ 24,537	\$ 32,317
Amortization of inventory and property "step up" to fair value	1,006	_
Amortization and impairment of purchased intangible assets, net of tax	3,244	2,617
Acquisition related transaction and integration costs	2,217	432
Loss (gain) from fair value adjustment of acquistion related contingent consideration	1,219	
Tax Benefit, European Restructuring		(9,245)
Restructuring, net of tax	(174)	32
Adjusted net income	\$ 32,049	\$ 26,153
Healthcare operating income	\$ 17,966	\$ 14,947
Amortization of inventory and property "step up" to fair value	1,257	_
Amortization and impairment of purchased intangible assets	5,098	3,947
Acquisition related transaction and integration costs	3,634	708
Loss (gain) from fair value adjustment of acquistion related contingent consideration	1,998	
Restructuring	(247)	52 c 10.654
Adjusted Healthcare operating income	\$ 29,706	\$ 19,654
Life Sciences operating income	\$ 11,945	\$ 12,539
Amortization and impairment of purchased intangible assets	18	26
Restructuring	(14)	
Adjusted Life Sciences operating income	\$ 11,949	\$ 12,565
Isomedix operating income	\$ 16,191	\$ 14,718
Amortization and impairment of purchased intangible assets	84	317
Restructuring	(25)	
Adjusted Isomedix operating income	\$ 16,250	\$ 15,035

STERIS Corporation Unaudited Supplemental Financial Data First Quarter Fiscal 2015 As of June 30, 2014

International Revenues as a% of Total \$5,92,92 \$7,92,92 International Revenues as a% of Total 2,02 2,02 Resume that q. q. 2,02 Healthcare 30,22 \$10,62 <th></th> <th>FY 2015</th> <th>FY 2014</th>		FY 2015	FY 2014
Consumables 110,045 89,024 43,228 144,724 Service 182,236 144,724 282,248 284,758 284,758 284,758 283,732 120,828 284,758 283,732 283,332 120,110 283,332 120,110 283,332 120,110 120,332 120,333 12			
Service 182.201 144.724 Total Revenues, net 5812.641 587.652 United States Revenues as a % of Total 351.351 358.383 United States Revenues as a % of Total 59.5292 59.298 International Revenues as a % of Total 29.529 79.299 International Revenues as a % of Total 35.5292 79.299 International Revenues as a % of Total 35.5292 79.299 International Revenues as a % of Total 35.5292 79.299 Second Data 0.1 0.1 0.1 Compatible 88.270 78.531 15.10 15.10 15.10 15.10 14.12 17.10 15.10 16.10 16.10 17.10 15.10 15.10 17.10 15.10 17.10 15.10 17.10 15.10 17.10 15.10			
Total Recursing			
Total Recumes, net			
United States Revenues as % of Total 5317.50 280.83.3 United States Revenues as % of Total 7.7 7.8 International Revenues 59,520 2.8 Secure Manage 2.9 2.2 Commendance 2.0 2.0 Recentage 8.0 2.0 2.0 Recentage 8.0 7.0 8.5 2.0 8.0 7.0 8.0 7.0 8.0 7.0 8.0 7.0 8.0 7.0 8.0 7.0 8.0 7.0 8.0 7.0 8.0 7.0 8.0 7.0 8.0 8.0 7.0 8.0 8.0 7.0 8.0 8.0 9.0 8.0 8.0 9.0 8.0 8.0 9.0 8.0 9.0 8.0 9.0 8.0 9.0 8.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 <	•		
United States Revenues as a % of Total	Total Revenues, net		
International Revenues as % of Total \$ 5,922 \$ 7,928 Segment hater q. 2 Resument Pate q. q. Revenues Total Equipment \$ 100,271 \$ 100,271 Consumables \$ 88,270 \$ 78,563 \$ 89,502 \$ 78,563 \$ 89,502 \$ 78,563 \$ 89,502 \$ 100,271 \$ 100,203 \$ 15,214 \$ 100,203 \$ 15,214 \$ 100,203 \$ 15,214 \$ 100,203 \$ 15,214 \$ 100,203 \$ 15,214 \$ 100,203 \$ 15,214 \$ 100,203 \$ 15,214 \$ 100,203 \$ 15,214 \$ 100,203 \$ 15,214 \$ 100,203 \$ 15,214 \$ 100,203 \$ 15,214 \$ 100,203 \$ 15,214 \$ 100,203 \$ 15,214 \$ 100,203 \$ 15,214 \$ 100,203 \$ 15,214 \$ 100,203 \$ 15,214 \$ 100,203 \$ 15,214 \$ 100,203 \$ 100,203 \$ 100,203 \$ 100,203 \$ 100,203 \$ 100,203 \$ 100,203 \$ 100,203 \$ 100,203 \$ 100,203 \$ 100,203 \$ 100,203 \$ 100,203 \$ 100,203 \$ 100,203 \$ 100,203 \$ 100,203	United States Revenues	\$317,351	\$288,353
Segment Data Q 22% Region Data Q1 21 HealtHard C C Revenues 80,20 78,50 Cospital Equipment \$102,271 \$101,674 Cosmables 80,20 78,55 Service 112,269 78,55 Total Recurring 20,53 157,214 Total Healthcare Revenues, net 20,70 14,94 Operating Income 71,96 14,94 Adjusted Operating Income (1) \$18,12 \$2,220 Capital Equipment \$18,12 \$2,220 Cost Sciences 21,75 20,471 Service \$18,715 72,224 Cost Sciences \$18,12 \$2,220 Cost Sciences \$18,12 \$2,220 Total Life Sciences Revenues \$18,17 \$2,220 Total Life Sciences Revenues \$58,61 \$59,915 Operating Income (1) \$1,25 \$2,50 State of Sciences Revenues \$1,23 \$2,22 Adjusted Operating Income (United States Revenues as a % of Total		78%
Reamed Data 91 91 Healtheare Revenus Capital Equipment \$02,271 \$10,674 Consumables \$82,20 \$8,533 Sevice \$12,200 \$8,531 Total Recurring \$20,503 \$15,214 Total Healthcare Revenues, net \$20,005 \$15,214 Adjusted Operating Income (1) \$20,000 \$19,562 Kir Sciences \$18,124 \$22,007 Revenue \$12,775 \$20,401 Consumables \$12,175 \$20,401 Service \$18,124 \$22,007 Total Recurring \$14,000 \$3,605 Total Recurring \$4,000 \$3,605 Total Life Sciences Revenues \$5,614 \$5,905 Total Life Sciences Revenues \$5,1913 \$4,224 Operating Income (1) \$1,935 \$2,525 Revenues \$5,193 \$4,224 Revenues \$2,6 \$5,25 Operating Income (Loss) \$1,935 \$1,025 Operating Income (Loss) <td></td> <td></td> <td></td>			
Revenus	International Revenues as a % of Total	23%	22%
Revenus	Segment Data	01	01
Capital Equipment \$10.02.71 \$10.1674 Consumbles 88.270 78.563 Service 112,269 78.6151 Total Recurring 350.2810 \$258.888 Operating Income 17.966 14.947 Adjusted Operating Income (1) 17.966 14.947 Adjusted Operating Income (1) \$18.124 \$22.200 Life Sciences 21.775 20.411 Capital Equipment \$18.124 \$22.202 Consumables \$18.124 \$22.202 Consumables \$18.715 17.224 Total Excurring \$18.04 \$3.901 Total Life Sciences Revenues \$3.614 \$3.901 Operating Income \$1.935 \$1.532 Adjusted Operating Income (1) \$1.935 \$1.935 Revenues \$5.193 \$4.224 Operating Income \$1.913 \$1.935 Adjusted Operating Income (1) \$1.925 \$1.925 Revenues \$3.6 \$5.5 Operating Income (Loss) \$1.935 \$1.93		_ _	
Service 12,269 78,563 Service 12,269 78,651 Total Recurring 200,539 157,214 Total Halithcare Reveuse, net 200,539 157,214 Operatin Income 17,966 14,947 Adjusted Operating Income (1) 20,000 19,654 Itie Sciences Revenue 21,775 20,471 Consumables 21,775 20,471 Service 18,175 21,722 Total Life Sciences Revenues 21,765 20,915 Total Life Sciences Revenues 5,8614 5,9915 Operating Income 11,949 12,555 Interpretation 11,949 12,555 Total Poduct Operating Income (1) 16,191 14,718 Adjusted Operating Income (1) 16,201 14,718 Adjusted Operating Income (1) 16,201 15,305 Total product Cost of Income (2) 12,302 15,305 Operating Income (2) 12,302 15,305 Total product Cost of Income (2) 12,302 <	Revenues		
Service 112.69 78.61 Total Recurring 200.53 15.71.42 Total Healthcare Revenues, net 530.201 253.888 Operating Income 17.966 14.947 Adjused Operating Income (1) 29.00 19.60 Life Sciences 18.72 20.241 Revenues 21.775 20.471 Consumables 18.715 21.224 Service 18.715 20.241 Service 18.715 20.241 Service Consumables 40.499 37.695 Total Recurring 40.499 37.695 Total Eccineres Revenues 5 56.164 55.915 Total Eccineres Revenues 5 56.164 55.915 Adjusted Operating Income (1) 19.50 15.05 Revenues 5 5.193 48.224 Operating Income 16.25 15.05 Total product Constrain Income (1) 16.25 15.05 Total product Constrain Income (1) 2.04 12.22 Revenues 2 6 5.05			
Total Recurring 200,539 157,214 Total Healthcare Revenues, net 302,810 \$28,888 Operating Income 17,966 14,947 Adjusted Operating Income (1) 29,06 10,684 Life Sciences Revenues 21,775 20,471 Consumables 21,775 20,471 Service 18,715 17,224 Total Recurring 40,49 37,632 Total Life Sciences Revenues 5,86,64 \$9,915 Operating Income 11,945 12,535 Sements 11,945 12,535 Incompany 16,191 14,718 Adjusted Operating Income (1) 16,29 15,035 Revenues 5,1193 84,224 Operating Income (1) 16,29 15,035 Adjusted Operating Income (1) 16,29 15,035 Revenues 5,193 84,224 Operating Income (Loss) 16,39 16,19 Adjusted Operating Income (1) 22,29 12,20 Total product			
Total Healthcare Revenues, net \$302,010 \$258,888 Operating Income 17,966 14,947 Adjused Operating Income (1) 29,706 19,648 Lite Sciences 30,201 19,658 Revenues 21,775 20,471 Capital Equipment \$18,124 \$2,220 Consumables 18,175 21,222 Consumables 40,490 37,695 Service 18,154 \$29,220 Total Recurring 40,490 37,695 Total Eckences Revenues \$5,161 \$5,995 Operating Income 11,945 12,539 Adjusted Operating Income (1) 11,945 14,724 Adjusted Operating Income (1) 16,191 14,724 Adjusted Operating Income (1) 16,191 14,724 Revenues \$ 2,6 \$ 5.2 Operating Income (Loss) 1,192 1,192 Operating Income (Loss) 2,192 1,192 Total product revenues 2,29,28 1,29,35 Total product revenues 2,29,28<			
Operating Income 17,966 14,947 Adjusted Operating Income (1) 29,706 19,658 Life Sciences 18,124 \$2,220 Consumables 21,775 20,471 Consumables 21,775 20,471 Service 18,115 17,224 Total Recurring 40,490 37,695 Total Life Sciences Revenues \$56,614 \$99,155 Operating Income 11,945 12,539 Adjusted Operating Income (1) 11,949 12,539 Adjusted Operating Income (1) 16,191 14,718 Revenues \$51,193 \$48,224 Operating Income 16,191 14,718 Adjusted Operating Income (1) 16,191 14,718 Adjusted Operating Income (1) 16,191 14,718 Revenues \$1,092 \$1,093 14,022 Operating Income (Loss) (1,934) 14,192 Total product cust of revenues 2 2 2 2 Total product cust of revenues 2 2 2 </td <td>Total Recurring</td> <td></td> <td></td>	Total Recurring		
Adjusted Operating Income (1) 29,706 19,654 Life Sciences Revenues Capital Equipment \$18,124 \$2,220 Consumables 21,775 20,471 Service 18,715 17,224 Total Recurring 40,490 37,695 Total Life Sciences Revenues \$ 36,614 \$ 59,015 Operating Income 11,945 12,539 Adjusted Operating Income (1) 10,949 12,555 Isometix Services \$ 11,949 12,555 Revenues \$ 11,949 12,555 Operating Income 16,191 14,718 Adjusted Operating Income (1) 16,291 14,718 Adjusted Operating Income (1) 16,295 15,035 Corporate and Other 16,191 14,718 Revenues \$ 26 \$ 625 Operating Income (Loss) 10 10 Other Date 21 40 Total product crost of revenues 229,494 22,928 Restructuring expenses 11,19 12,294	Total Healthcare Revenues, net	\$302,810	\$258,888
Adjusted Operating Income (1) 29,706 19,654 Life Sciences Revenues Capital Equipment \$18,124 \$2,220 Consumables 21,775 20,471 Service 18,715 17,224 Total Recurring 40,490 37,695 Total Life Sciences Revenues \$ 36,614 \$ 59,015 Operating Income 11,945 12,539 Adjusted Operating Income (1) 10,949 12,555 Isometix Services \$ 11,949 12,555 Revenues \$ 11,949 12,555 Operating Income 16,191 14,718 Adjusted Operating Income (1) 16,291 14,718 Adjusted Operating Income (1) 16,295 15,035 Corporate and Other 16,191 14,718 Revenues \$ 26 \$ 625 Operating Income (Loss) 10 10 Other Date 21 40 Total product crost of revenues 229,494 22,928 Restructuring expenses 11,19 12,294	Operating Income	17,966	14,947
Life Sciences Revenues 1 2 2,22,20 2,00 2,17,75 2,04,71 2,04,71 2,04,71 2,04,71 2,04,71 2,04,71 2,04,71 2,04,71 2,04,71 2,04,71 2,04,71 2,04,71 3,05,95	Adjusted Operating Income (1)		19,654
Capital Equipment \$18,124 \$2,220 Consumables 21,775 20,471 Service 18,715 17,224 Total Recurring 40,400 37,695 Total Life Sciences Revenues \$58,614 \$59,915 Operating Income 11,945 12,539 Adjusted Operating Income (1) 11,949 12,565 Revenues \$11,931 \$48,224 Operating Income 16,159 14,718 Adjusted Operating Income (1) 16,250 15,035 Corporate and Other \$2 \$6 Revenues \$2 \$6 Operating Income (Loss) (1,934) (1,192) Other Data \$2 \$6 Operating Income (Loss) (1,934) (1,192) Other Data \$1 \$0 Total product revenues \$2 \$6 Total product cost of revenues \$12,935 \$12,938 Restructuring expense \$1 \$2 \$3 Total product gost of revenues \$1 \$2	Life Sciences		
Consumables 21,775 20,471 Service 18,715 17,224 Total Recurring 40,490 37,695 Total Life Sciences Revenues \$ 58,614 \$ 59,915 Operating Income 11,949 12,539 Adjusted Operating Income (1) 11,949 12,539 Somedix Services 11,949 12,505 Revenues 5 5,1193 \$ 48,224 Operating Income 16,191 14,718 Adjusted Operating Income (1) 16,250 15,035 Corporate and Other \$ 26 \$ 25 Revenues \$ 26 \$ 25 Operating Income (Loss) 11,929 11,929 Oberating Income (Loss) 20 11,929 11,929 Object to Type (Loss) 20 11,939 11,939 11,939 11,939 11,939 11,939 11,939 11,939 12,928 12,928 12,928 129,338 12,928 129,338 12,928 129,338 12,935 12,938 12,938 129,338 12,938 <t< td=""><td>Revenues</td><td></td><td></td></t<>	Revenues		
Service 18,715 17,224 Total Recurring 30,600 37,695 Operating Income 11,945 12,535 Adjusted Operating Income (1) 11,949 12,555 Revenues \$ 51,193 \$ 48,224 Operating Income 16,191 14,718 Adjusted Operating Income (1) 16,250 15,035 Corporate and Other Revenues 2 6 8 25 Operating Income (Loss) 19,394 1,192 Operating Income (Loss) 19,395 1,293 Total product revenues 2 8 8 2 Total product revenues 330,440 222,928 Restructuring expense 41,194 — Total product cost of revenues 129,975 129,538 Restructuring expense (114) — Total product gense profit, adjusted (1) 10,158 9,309 As a percentage, adjusted (1) 112,555 12,558 Total service revenues 182,203 144,724 Total service gross profit 69			
Total Recurring 40,40g 37,685 Total Life Sciences Revenues \$ 58,614 \$ 59,915 Operating Income 11,945 12,539 Adjusted Operating Income (1) 11,949 12,565 Isometic Services 8 51,193 \$ 48,224 Revenues \$ 51,193 \$ 48,224 Operating Income 16,191 14,718 Adjusted Operating Income (1) 16,250 15,035 Corporate and Other 2 6 6.25 Revenues 2 6 6.25 Operating Income (Loss) 1 1 Other Data 2 6.25 Total product revenues 2 6 6.25 Operating Income (Loss) 2 1 Total product revenues 2 2 6.25 Total product revenues 2 <td></td> <td></td> <td></td>			
Total Life Sciences Revenues \$ 58,614 \$ 59,015 Operating Income 11,945 12,536 Adjusted Operating Income (1) 11,949 12,565 Isomedix Services 8 51,193 \$ 48,224 Revenues \$ 51,193 \$ 48,224 Operating Income (1) 16,191 14,718 Adjusted Operating Income (1) 16,250 15,035 Corporate and Other 2 6 <th< td=""><td></td><td></td><td></td></th<>			
Operating Income 11,945 12,539 Adjusted Operating Income (1) 11,949 12,565 Revenues \$1,193 \$48,224 Operating Income 16,191 14,718 Adjusted Operating Income (1) 16,250 15,055 Corporate and Other Revenues \$ 26 \$ 625 Operating Income (Loss) 0 1,934 1,192 Observating Income (Loss) 0 1 1 Operating Income (Loss) 0 1 1 Observating Income (Loss) 0 1 1 Operating Income (Loss) 0 1 1 Operating Income (Loss) 0 1 1 Total product Cost 2 2 6 5 6 5 6 5 6 5 6 2 6 5 6 2 6 2 2 9 2 6 2 2 9 2 8 2 2 9 2 8 2			
Adjusted Operating Income (1) 11,949 12,565 Isometic Services 8 14,192 48,224 Qoperating Income 16,191 14,718 48,224 Operating Income 16,191 14,718 48,224 Adjusted Operating Income (1) 16,250 15,355 15,355 Corporate and Other 2 6 6 5 6 5 6 5 6 5 6 5 6 5 6 5 6 5 6 5 6 5 6 5 6 5 6 5 6 5 5 6 5 5 6 5 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2	Total Life Sciences Revenues	\$ 58,614	\$ 59,915
Isomedix Services Revenues \$ 5,1,93 \$ 48,224 Operating Income 16,191 14,718 Adjusted Operating Income (1) 16,250 15,035 Corporate and Other "Total Product Tevenues" \$ 6 \$ 6,255 Operating Income (Loss) (1,934) (1,192) Ober Data Q Q Q Product 230,440 222,928 Total product revenues 30,440 222,928 Total product cost of revenues (114) — Total product revenues (114) — Amortization of inventory "step up" to fair value 1,234 — Total product crost of revenues, adjusted (1) 101,585 93,390 As a percentage, adjusted (1) 41,90 41,90 Service 101,585 93,390 As a percentage, adjusted (1) 41,90 41,90 Service 112,575 91,268 Total service revenues 182,203 144,724 Total service gross profit 69,628 53,456	Operating Income	11,945	12,539
Revenues \$ 51,193 \$ 48,224 Operating Income 16,191 14,718 Adjusted Operating Income (1) 16,250 15,035 Corporate and Other 8 26 6.25 Revenues 26 6.25 Operating Income (Loss) (1,934) (1,192) Other Data 9 6 6.25 Total product revenues 230,440 222,928 Total product cost of revenues 230,440 222,928 Total product cost of revenues 230,440 222,928 Restructuring expense (114) - Amortization of inventory "step up" to fair value 1,234 - Total product cost of revenues, adjusted (1) 101,585 33,39 As a percentage, adjusted (1) 101,585 33,39 As a percentage, adjusted (1) 41,724 41,94 Service 112,575 91,268 Total service revenues 112,575 91,268 Total service revenues 38,296 33,596 As a percentage, adjusted (1) 47,244 </td <td></td> <td>11,949</td> <td>12,565</td>		11,949	12,565
Operating Income 16,191 14,718 Adjusted Operating Income (1) 16,250 15,035 Corporate and Other 2 6,25 6,25 Revenues 2.6 6,25 6,25 7,25 6,25 7,25 7,25 7,25 7,25 7,25 7,25 8,25	Isomedix Services		
Adjusted Operating Income (1) 16,250 15,035 Corporate and Other 8 6 8 6 8 6 6 5 6 6 6 7 6 7 6 7 8 8 9 7 9 3 9 9 9 3 3 9 9 3 3 9 9 3 3 9 9 3 3 9 9 9 3			
Corporate and Other Revenues \$ 26 \$ 625 Operating Income (Loss) \$ 1,192 Other Data QI QI Product 230,440 222,928 Total product crevenues 329,75 129,538 Restructuring expenses (114) — Amortization of inventory "step up" to fair value 1,234 — Total product cost of revenues, adjusted (1) 128,855 129,538 Total product gross profit, adjusted (1) 101,585 93,390 As a percentage, adjusted (1) 41,794 41,996 Service 122,033 144,724 Total service evenues 112,575 91,268 Total service gross profit 69,628 53,456 As a percentage 38,296 33,696 As a percentage 312,131 146,846 As a percentage, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 317,101 516,346 Healthcare Backlog 152,032 \$120,170 Healthcare Backlog 45,969 44,562 <td>-</td> <td></td> <td></td>	-		
Revenues \$ 26 \$ 625 Operating Income (Loss) (1,934) (1,192) Other Data q1 q1 Product 230,440 222,928 Total product revenues 129,975 129,538 Restructuring expense (114) — Amortization of inventory "step up" to fair value 1,234 — Total product cost of revenues, adjusted (1) 128,855 129,538 Total product gross profit, adjusted (1) 101,585 93,390 As a percentage, adjusted (1) 41.9% Service 1 1 1 Total service revenues 182,203 144,724 1 Total service gross profit 69,628 53,456 As a percentage 38.2% 36,99% Total Company gross profit margin, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 41.5% 39,9% Healthcare Backlog \$125,032 \$120,170 Healthcare Backlog \$45,969 44,562 Total Backlog 45,969 44,562 </td <td></td> <td>16,250</td> <td>15,035</td>		16,250	15,035
Operating Income (Loss) (1,934) (1,192) Other Data q1 q1 Product 20 q2 Total product revenues 230,440 222,928 Total product cost of revenues 129,975 129,538 Restructuring expense (114) — Amortization of inventory "step up" to fair value 1,234 — Total product cost of revenues, adjusted (1) 101,585 93,390 As a percentage, adjusted (1) 44.1% 41.9% Service 182,033 144,724 Total service revenues 182,203 144,724 Total service cost of revenues 112,575 91,268 Total service gross profit 69,628 53,456 As a percentage 38.2% 36.9% Total Company gross profit margin, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 311,257 33.9% Healthcare Backlog 512,032 \$120,170 Life Sciences Backlog 45,962 44,562 Total Backlog 517,001 \$1	•		
Other Data Q1 Q1 Product 230,440 222,928 Total product revenues 129,975 129,538 Restructuring expense (114) — Amortization of inventory "step up" to fair value 1,234 — Total product cost of revenues, adjusted (1) 128,855 129,538 Total product gross profit, adjusted (1) 101,585 93,390 As a percentage, adjusted (1) 44.1% 41.9% Service 112,575 91,268 Total service revenues 112,575 91,268 Total service gross profit 69,628 53,456 As a percentage 38.2% 36.9% Total Service gross profit margin, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 31,205 33.9% Healthcare Backlog \$12,070 \$12,070 Life Sciences Backlog 45,969 45,562 Total Backlog \$171,001 \$164,732 Free Cash Flow \$23,093 \$10,964			
Product 30,440 222,928 Total product revenues 230,440 222,928 Total product cost of revenues 129,975 129,538 Restructuring expense (114) — Amortization of inventory "step up" to fair value 1,234 — Total product cost of revenues, adjusted (1) 101,585 129,538 Total product gross profit, adjusted (1) 41,90 44,19 Service 38,203 144,724 Total service revenues 182,203 144,724 Total service gross profit 69,628 53,456 Total Service gross profit 69,628 53,456 Total Company gross profit margin, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 41,5% 39,9% Healthcare Backlog \$120,170 45,969 44,562 Total Backlog \$171,001 \$164,732 5164,732 Total Backlog \$171,001 \$164,732 5164,732 Total Backlog \$171,001 \$164,732 5164,732 5164,732 5164,732 5164,7	Operating Income (Loss)	(1,934)	(1,192)
Product 30,440 222,928 Total product revenues 230,440 222,928 Total product cost of revenues 129,975 129,538 Restructuring expense (114) — Amortization of inventory "step up" to fair value 1,234 — Total product cost of revenues, adjusted (1) 101,585 129,538 Total product gross profit, adjusted (1) 41,90 44,19 Service 38,203 144,724 Total service revenues 182,203 144,724 Total service gross profit 69,628 53,456 Total Service gross profit 69,628 53,456 Total Company gross profit margin, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 41,5% 39,9% Healthcare Backlog \$120,170 45,969 44,562 Total Backlog \$171,001 \$164,732 5164,732 Total Backlog \$171,001 \$164,732 5164,732 Total Backlog \$171,001 \$164,732 5164,732 5164,732 5164,732 5164,7	Other Data	01	01
Total product cost of revenues 129,975 129,538 Restructuring expense (114) — Amortization of inventory "step up" to fair value 1,234 — Total product cost of revenues, adjusted (1) 128,855 129,538 Total product gross profit, adjusted (1) 44.1% 41.9% As a percentage, adjusted (1) 44.1% 41.9% Service 182,203 144,724 Total service revenues 112,575 91,268 Total service gross profit 69,628 53,456 As a percentage 38.2% 36.9% Total Company gross profit margin, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 41.5% 39.9% Healthcare Backlog \$125,032 \$120,170 Life Sciences Backlog 45,969 44,562 Total Backlog \$171,001 \$164,732 Free Cash Flow \$23,093 \$10,964			<u> </u>
Total product cost of revenues 129,975 129,538 Restructuring expense (114) — Amortization of inventory "step up" to fair value 1,234 — Total product cost of revenues, adjusted (1) 128,855 129,538 Total product gross profit, adjusted (1) 44.19 41.99 As a percentage, adjusted (1) 44.19 41.99 Service 182,203 144,724 Total service revenues 112,575 91,268 Total service gross profit 69,628 53,456 As a percentage 38.29 36.99 Total Company gross profit margin, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 41.59 39.99 Healthcare Backlog \$125,032 \$120,170 Life Sciences Backlog 45,969 44,562 Total Backlog \$171,001 \$164,732 Free Cash Flow \$23,093 \$10,964	Total product revenues	230,440	222,928
Amortization of inventory "step up" to fair value 1,234 — Total product cost of revenues, adjusted (1) 128,855 129,538 Total product gross profit, adjusted (1) 101,585 93,390 As a percentage, adjusted (1) 44.1% 41.9% Service 182,203 144,724 Total service revenues 112,575 91,268 Total service gross profit 69,628 53,456 As a percentage 38.2% 36.9% Total Company gross profit margin, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 41.5% 39.9% Healthcare Backlog \$125,032 \$120,170 Life Sciences Backlog \$15,969 44,562 Total Backlog \$171,001 \$164,732 Free Cash Flow \$23,093 \$10,964		129,975	129,538
Total product cost of revenues, adjusted (1) 128,855 129,538 Total product gross profit, adjusted (1) 101,585 93,390 As a percentage, adjusted (1) 44.1% 41.9% Service 182,203 144,724 Total service revenues 112,575 91,268 Total service gross profit 69,628 53,456 As a percentage 38.2% 36.9% Total Company gross profit margin, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 41.5% 39.9% Healthcare Backlog \$125,032 \$120,170 Life Sciences Backlog 45,969 44,562 Total Backlog \$171,001 \$164,732 Free Cash Flow \$23,093 \$10,964	Restructuring expense	(114)	_
Total product gross profit, adjusted (1) 101,585 93,390 As a percentage, adjusted (1) 44.1% 41.9% Service 182,203 144,724 Total service revenues 112,575 91,268 Total service gross profit 69,628 53,456 As a percentage 38.2% 36.9% Total Company gross profit margin, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 41.5% 39.9% Healthcare Backlog \$125,032 \$120,170 Life Sciences Backlog 45,969 44,562 Total Backlog \$171,001 \$164,732 Free Cash Flow \$23,093 \$10,964	Amortization of inventory "step up" to fair value	1,234	
As a percentage, adjusted (1) 44.1% 41.9% Service Total service revenues 182,203 144,724 Total service cost of revenues 112,575 91,268 Total service gross profit 69,628 53,456 As a percentage 38.2% 36.9% Total Company gross profit margin, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 41.5% 39.9% Healthcare Backlog \$125,032 \$120,170 Life Sciences Backlog 45,969 44,562 Total Backlog \$171,001 \$164,732 Free Cash Flow \$23,093 \$10,964	Total product cost of revenues, adjusted (1)	128,855	129,538
Service Total service revenues 182,203 144,724 Total service cost of revenues 112,575 91,268 Total service gross profit 69,628 53,456 As a percentage 38.2% 36.9% Total Company gross profit margin, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 41.5% 39.9% Healthcare Backlog \$125,032 \$120,170 Life Sciences Backlog 45,969 44,562 Total Backlog \$171,001 \$164,732 Free Cash Flow \$23,093 \$10,964	Total product gross profit, adjusted (1)	101,585	93,390
Total service revenues 182,203 144,724 Total service cost of revenues 112,575 91,268 Total service gross profit 69,628 53,456 As a percentage 38.2% 36.9% Total Company gross profit margin, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 41.5% 39.9% Healthcare Backlog \$125,032 \$120,170 Life Sciences Backlog 45,969 44,562 Total Backlog \$171,001 \$164,732 Free Cash Flow \$23,093 \$10,964	As a percentage, adjusted (1)	44.1%	41.9%
Total service cost of revenues 112,575 91,268 Total service gross profit 69,628 53,456 As a percentage 38.2% 36.9% Total Company gross profit margin, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 41.5% 39.9% Healthcare Backlog \$125,032 \$120,170 Life Sciences Backlog 45,969 44,562 Total Backlog \$171,001 \$164,732 Free Cash Flow \$23,093 \$10,964			
Total service gross profit 69,628 53,456 As a percentage 38.2% 36.9% Total Company gross profit margin, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 41.5% 39.9% Healthcare Backlog \$125,032 \$120,170 Life Sciences Backlog 45,969 44,562 Total Backlog \$171,001 \$164,732 Free Cash Flow \$23,093 \$10,964			
As a percentage 38.2% 36.9% Total Company gross profit margin, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 41.5% 39.9% Healthcare Backlog \$125,032 \$120,170 Life Sciences Backlog 45,969 44,562 Total Backlog \$171,001 \$164,732 Free Cash Flow \$23,093 \$10,964			
Total Company gross profit margin, adjusted (1) 171,213 146,846 As a percentage, adjusted (1) 41.5% 39.9% Healthcare Backlog \$125,032 \$120,170 Life Sciences Backlog 45,969 44,562 Total Backlog \$171,001 \$164,732 Free Cash Flow \$23,093 \$10,964			
As a percentage, adjusted (1) 41.5% 39.9% Healthcare Backlog \$125,032 \$120,170 Life Sciences Backlog 45,969 44,562 Total Backlog \$171,001 \$164,732 Free Cash Flow \$23,093 \$10,964			36.9%
Healthcare Backlog \$125,032 \$120,170 Life Sciences Backlog 45,969 44,562 Total Backlog \$171,001 \$164,732 Free Cash Flow \$23,093 \$10,964			
Life Sciences Backlog 45,969 44,562 Total Backlog \$171,001 \$164,732 Free Cash Flow \$23,093 \$10,964			39.9%
Total Backlog \$171,001 \$164,732 Free Cash Flow \$23,093 \$10,964			
Free Cash Flow \$ 23,093 \$ 10,964	-		
Net Debt \$500,804 \$347,862			
	Net Debt	\$500,804	\$347,862

⁽¹⁾ Non-GAAP financial measures are presented with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision making. These amounts are disclosed so that the reader has the same financial data that management uses with the belief that it will assist investors and other readers in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented.

We believe that the presentation of these non-GAAP financial measures, when considered along with our GAAP financial measures and the reconciliation to the corresponding GAAP financial measures, provide the reader with a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. It is important for the reader to note that the non-GAAP financial measure used may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.

This supplemental data is consistent with publicly disclosed information provided in quarterly conference calls, earnings releases and SEC filings, and is subject to all definitions, precautions and limitations contained in those disclosures. Please see the Company's most recent 10-K for definitions (and reconciliation where appropriate) of adjusted measures, backlog, free cash flow and net debt.